AKT1 and ovarian serous cystadenocarcinoma: In addition, we confirmed PTEN mutations as putative resistance markers in the PIK3CA mutant ovarian serous cystadenocarcinoma cell line TOV-21G, which should have been sensitive to the AKT inhibitor GSK690693 according to its sensitivity biomarker (Figure 1E).29